Dose-Finding, Safety and Efficacy Study of RX-0201 Plus Everolimus in Metastatic Renal Cell Cancer
Status:
Terminated
Trial end date:
2018-05-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the maximum tolerated dose of RX-0201, up to a
target dose of 250 mg/m^2/day, when given in combination with everolimus (Stage 1), and to
assess the safety and efficacy of RX-0201 plus everolimus, in subjects with metastatic renal
cell cancer (Stage 2).